Company / Operating Cash Flow
Akebia Therapeutics, Inc. Operating Cash Flow History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$68.0M
FY2025
5-year range
-$257.4M / $68.0M
FY2021-FY2025
Trend
+267.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow changed +267% YoY in FY2025, a notable deviation from the 9-year average annual change of +50%.
Based on SEC 10-K filings.
$68M in FY2025.
Improved from -$23M to $68M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 267.2% year-over-year.
- Lowest operating cash flow in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $68.0M | +267.2% |
| FY2024 | -$40.7M | -73.9% |
| FY2023 | -$23.4M | +68.0% |
| FY2022 | -$73.2M | +71.6% |
| FY2021 | -$257.4M | -164.1% |
| FY2020 | -$97.5M | -73.6% |
| FY2019 | -$56.2M | -197.0% |
| FY2018 | $57.9M | +611.0% |
| FY2015 | -$11.3M | -57.1% |
| FY2014 | -$7.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026